Literature DB >> 30569586

Adaptive behavior in adolescents and adults with Down syndrome: Results from a 6-month longitudinal study.

Gail A Spiridigliozzi1, Celia Goeldner2, Jamie Edgin3, Sarah J Hart4, Jana Noeldeke2, Lisa Squassante2, Jeannie Visootsak5, James H Heller, Omar Khwaja2, Priya S Kishnani4, Xavier Liogier d'Ardhuy2.   

Abstract

Measures of adaptive behavior are important in the assessment and treatment of individuals with intellectual disabilities (ID). The purpose of the current study was to evaluate the stability of an established and a novel measure of adaptive behavior over time, and their suitability as outcome measures in clinical trials targeting individuals with Down syndrome (DS). This 6-month, longitudinal, noninterventional, multinational study included adolescents (12-17 years) and adults (18-30 years) with DS. Participants were from seven countries (11 different sites) with English, Spanish and French as their native language. The Vineland Adaptive Behavior Scales-II (VABS-II) and a newly developed Clinician Global Impression (CGI) scale were administered at baseline, 1 and 6 months. Adults had lower composite standard scores on all domains of the VABS-II compared with adolescents. The communication domain was a weakness relative to the socialization and daily living skills domains on the VABS-II and the CGI-Severity scale. These findings were stable over 6 months, as exhibited by high intraclass correlations (>0.75). These results provide valuable baseline data for use in trial design and endpoint selection for studies including individuals with DS. ClinicalTrials.gov identifier: NCT01580384.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  CGI-I; CGI-S; Down syndrome; VABS-II; adaptive behavior; intellectual disability

Mesh:

Year:  2018        PMID: 30569586     DOI: 10.1002/ajmg.a.60685

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  3 in total

1.  A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome.

Authors:  Celia Goeldner; Priya S Kishnani; Brian G Skotko; Julian Lirio Casero; Joerg F Hipp; Michael Derks; Maria-Clemencia Hernandez; Omar Khwaja; Sian Lennon-Chrimes; Jana Noeldeke; Sabine Pellicer; Lisa Squassante; Jeannie Visootsak; Christoph Wandel; Paulo Fontoura; Xavier Liogier d'Ardhuy
Journal:  J Neurodev Disord       Date:  2022-02-05       Impact factor: 4.025

2.  Executive functions and adaptive behaviour in individuals with Down syndrome.

Authors:  S Onnivello; S Colaianni; F Pulina; C Locatelli; C Marcolin; G Ramacieri; F Antonaros; B Vione; A Piovesan; S Lanfranchi
Journal:  J Intellect Disabil Res       Date:  2021-11-09

3.  Is the Age of Developmental Milestones a Predictor for Future Development in Down Syndrome?

Authors:  Chiara Locatelli; Sara Onnivello; Francesca Antonaros; Agnese Feliciello; Sonia Filoni; Sara Rossi; Francesca Pulina; Chiara Marcolin; Renzo Vianello; Enrico Toffalini; Giuseppe Ramacieri; Anna Martelli; Giulia Procaccini; Giacomo Sperti; Maria Caracausi; Maria Chiara Pelleri; Lorenza Vitale; Gian Luca Pirazzoli; Pierluigi Strippoli; Guido Cocchi; Allison Piovesan; Silvia Lanfranchi
Journal:  Brain Sci       Date:  2021-05-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.